28 Jul Delays in Denosumab (Prolia®) Injections Linked to Increased Risk of Fractures
MedicalResearch.com Interview with:
Daniel Hal Solomon, MD, MPH
Associate Physician, Brigham and Women’s Hospital
Professor of Medicine, Harvard Medical School
Brigham and Women’s Hospital
Department of Medicine
Boston, MA 02115
Editor’s note: Prolia® is the trade name for denosumab.
MedicalResearch.com: What is the background for this study?
Response: We conducted this study to assess whether delays in denosumab (injections were associated with an increased risk of fractures. In a prior study, we found that the improvements in bone mineral density were reduced among patients who delayed injections.
MedicalResearch.com: What are the main findings?
Response: In the current study, we also found that delays in denosumab injections of > 4 months were associated with an increased risk of fractures, especially vertebral fractures.
MedicalResearch.com: What should readers take away from your report?
Response: Readers should understand that delays of over 4 months are associated with an increased risk of fracture, making on time injections more important.
MedicalResearch.com: What recommendations do you have for future research as a result of this work?
Response: We are examining systems for improving on time injections.
Disclosures: I have received grants from Amgen, unrelated to the present study.
Annals of Internal Medicine 0 0:0
The information on MedicalResearch.com is provided for educational purposes only, and is in no way intended to diagnose, cure, or treat any medical or other condition. Always seek the advice of your physician or other qualified health and ask your doctor any questions you may have regarding a medical condition. In addition to all other limitations and disclaimers in this agreement, service provider and its third party providers disclaim any liability or loss in connection with the content provided on this website.